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Abstract 
Introduction:  Systemic inflammatory response syndrome (SIRS) is frequently observed after 
extracorporeal membrane oxygenation (ECMO) decannulation; however, these issues have not been 
investigated well in the past.  
Methods:  Retrospective chart review was performed to identify post-ECMO SIRS phenomenon, defined 
by exhibiting 2/3 of the following criteria: fever, leukocytosis, and escalation of vasopressors.  The 
patients were divided into 2 groups: patients with documented infections (Group I) and patients with true 
SIRS (Group TS) without any evidence of infection.  Survival and pre-, intra- and post- ECMO risk 
factors were analyzed. 
Results:  Among 62 ECMO survivors, 37 (60%) patients developed the post-ECMO SIRS phenomenon, 
including Group I (n= 22) and Group TS (n=15).  The 30-day survival rate of Group I and TS was 77% 
and 100%, respectively (p=0.047), although pre-decannulation risk factors were identical. 
Conclusions: SIRS phenomenon after ECMO decannulation commonly occurs.  Differentiating between 
the similar clinical presentations of SIRS and infection is important and will impact clinical outcomes.  
 
Key words: ECMO; SIRS; infection. 
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List of Abbreviations 
APACHE: acute physiology and chronic health evaluation. 
ECMO: extracorporeal membrane oxygenation. 
E-CPR: extracorporeal membrane oxygenation assisted cardiopulmonary resuscitation. 
MELD: model for end-stage liver disease. 
SAPS: simplified acute physiology score. 
SIRS: systemic inflammatory response syndrome. 
WBC: white blood cell. 
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Introduction 
Extracorporeal membrane oxygenation (ECMO) support is well-established technology that 
provides both circulatory and respiratory support in patients with severe refractory cardiopulmonary 
failure.1  ECMO stabilizes hemodynamics quickly in patients with severe hemodynamic and respiratory 
instability.  While hemodynamics are restored and stabilized by ECMO, end-organ function is allowed to 
recover. 2  Patients on ECMO are decannulated once organ recovery criteria are met.  If cardiac recovery 
has not occurred, the patient can be assessed for implantable mechanical support. 
Systemic inflammatory response syndrome (SIRS), including fever, leukocytosis, and 
vasodilation is often observed during ECMO and related to either the ECMO circuit and/or the patient 
disease processes. 3 This SIRS phenomenon during ECMO generally resolves as the primary disease is 
treated; the SIRS phenomenon should always be absent at the time of decannulation.  However, we have 
often encountered the SIRS phenomenon after ECMO decannulation.  The long-standing cannula and 
extracorporeal circuit kept for a period of time during ECMO may be responsible for blood stream 
infections. 4  Similarly, long-term ventilator support may increase the chance of ventilator associated 
pneumonia and subsequent development of sepsis. 4  Additionally, surgical interventions required for 
repair of the vessel after decannulation may complicate the postoperative course.  Understanding the 
nature of the post-decannulation SIRS phenomenon and differentiating the similar clinical presentations 
of SIRS from sepsis could be important for clinicians who manage ECMO patients, since this can affect 
patient outcomes.  Although we frequently observe these SIRS phenomena after ECMO decannulation, to 
our knowledge, no research about this issue has been undertaken.  Thus, we performed this retrospective 
study in order to 1) identify the incidence of post-decannulation SIRS, 2) find the incidence of infection, 
3) investigate the possibility of differentiating SIRS from infection, and 4) study the outcome of patients 
based on the presence of SIRS or infection. 
Methods 
 Between July 2010 and June 2014, 122 ECMO procedures via peripheral cannulation were 
performed at our institution. 4, 5  Medical records of patients who survived ECMO were reviewed, and 
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their pre-, intra-, and post-ECMO data were entered into a structured database after approval from the 
institutional review board.  Patients who died within 48 hours of ECMO decannulation were excluded 
from the study. 
Veno-arterial ECMO from femoral cannulation was used for patients with cardiac failure. 4  
Patients with respiratory failure underwent veno-venous ECMO via single right internal jugular 
cannulation, 5 although a minority of these patients underwent veno-arterial ECMO due to anatomy, 
severe hypotension, ventricular failure, or technical reasons.  ECMO circuits included a Rotaflow 
centrifugal pump (Maquet, Rastatt, Germany) and a Quadrox-D diffusion membrane hollow-fiber 
oxygenator (Maquet, Rastatt, Germany).  All patients were afebrile without evidence of on-going active 
infection or SIRS at the time of decannulation, per our institutional practice guidelines.  ECMO 
decannulation was performed in the operating room with direct vessel repair. 4, 5  Peri-operative 
antibiotics were used for only 24 hours post-decannulation unless a course of antibiotics initiated during 
ECMO were being completed.  Antibiotics were extended past 24 hours post-decannulation based on 
clinical judgment if a patient exhibited signs of a new infection. 
Post-ECMO decannulation “SIRS phenomenon” was defined as having 2 out of the 3 of the 
following criteria after ECMO decannulation regardless of the presence of infection: fever (temperature > 
101.5 °F), leukocytosis (white blood cell [WBC] >12,000, or 25% increase from pre-decannulation 
baseline), and escalation of vasopressors compared to the patient’s pre-decannulation baseline.  Other 
diagnostic criteria of the SIRS, such as increase in heart rate or respiratory rate were not used for this 
study since these may be artificially modified due to the use of inotropes, degree of sedation, and 
ventilator settings.  The patients who were found to have the SIRS phenomenon were further divided into 
2 groups: SIRS phenomenon with evidence of infection (Group I) and true SIRS without evidence of 
infection (Group TS).  Evidence of infection included positive blood, sputum, wound, or stool cultures.  
The presence of the infection was divided into “carried over” which was defined as infection present at 
the time of cannulation or during ECMO, but controlled appropriately at the time of the decannulation, 
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and “new infection after ECMO decannulation” which was defined as culture positive infection diagnosed 
after ECMO decannulation.  Figure 1 illustrates the division of patient groups used in the study. 
Risk factors including patient demographics, pre-ECMO, intra-ECMO, and post-ECMO 
parameters were retrospectively analyzed to identify risk factors of developing the post-decannulation 
SIRS phenomenon and variables that can differentiate between post-decannulation infection and true 
SIRS.  Categorical variables and continuous variables were compared between the two groups using Chi-
Square analysis (Fisher tests if small sample size) or two-tailed t-test, as appropriate.  A p-value of less 
than 0.05 was considered to be significant. 
Results 
A total of 62 patients who survived ECMO were identified during the study period.  Among 
them, 37 (60%) patients developed the SIRS phenomenon based on the criteria.  Table 1 compared the 
demographics of the patients with post-decannulation SIRS phenomenon vs. no SIRS phenomenon.  
There were no significant differences in pre-ECMO risk factors, hematology, or chemistry values except 
for following: pre-ECMO lactate (4.8 ± 4.6 mmol/L for the patients with SIRS phenomenon vs. 2.9 ± 2.4 
mmol/L without SIRS phenomenon, p=0.038) and alanine aminotransferase (93 ± 190 IU/L vs. 288 ± 440 
IU/L, p=0.041).  Pre-decannulation demographics, pre-decannulation laboratory data, and length of 
ECMO were similar between those who developed post-decannulation SIRS phenomenon and those who 
did not.  Similarly, complications during ECMO and transfusions during ECMO (15 ± 20 units packed 
blood cell transfusion for those with SIRS phenomenon vs. 16 ± 18 units for those without SIRS 
phenomenon) were not significantly different.  The 30-day survival after ECMO decannulation was not 
different between with and without post-decannulation SIRS phenomenon (86% with the SIRS 
phenomenon vs. 76% without the SIRS phenomenon, p=0.289). 
Among those who had post-decannulation SIRS phenomenon, 22 patients (59% among SIRS 
phenomenon patients, 35% among all studied patients) had evidence of infection (Group I): bacteremia in 
7 (32%), pneumonia in 12 (56%), surgical site infection in 3 (14%), and Clostridium difficile infection in 
1 (4.5%), with 5 patients having overlapping infections.  Out of these 22 patients, 9 patients (41%) had 
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carried over an infection that developed either at the time of ECMO cannulation or during ECMO, 
although these infections had been controlled with appropriate antibiotics.  The remaining 13 patients 
(59%) had infections that developed after decannulation.  In Group TS, which included 15 patients (41% 
among SIRS phenomenon patients, 24% among all studied patients), no evidence of infection was found 
despite aggressive investigation of possible sources of infection including serial cultures and imaging 
tests.  Demographics of Group I and Group TS are shown in Table 2.  Risk factor analysis showed that 
metabolic acidosis at the time of ECMO cannulation was less frequently observed in Group I than in 
Group TS (Group I vs. Group TS: pH 7.32 ± 0.12 vs. pH 7.23 ± 0.11, p=0.031; and HCO3 23 ± 6 mmol/L 
vs. HCO3 19 ± 5 mmol/L, p=0.038 respectively).  Pre-ECMO demographics, pre-ECMO laboratory data, 
length of ECMO, pre-decannulation laboratory data, complications during ECMO, and transfusions 
during ECMO were not different between Group I and Group TS. 
Individual components of the SIRS phenomenon after decannulation of ECMO are shown in 
Table 3.  Development of fever (initial day of fever, length of fever), leukocytosis (initial day of 
leukocytosis, duration of leukocytosis), and vasopressor usage (number of patients requiring vasopressor 
escalation, duration of vasopressor use) were similar between Group I and Group TS.  In comparing 
variables of SIRS phenomenon between the two groups, the only difference found was the peak WBC 
count (Group I vs. Group TS: 30.1 ± 13.3 B/L vs. 21.3 ± 7.7 B/L, p=0.04).  Peak WBC counts above 
30,000 were more often found in Group I (46%) than in Group TS (14%), p=0.026.  Regardless of the 
presence of infection or not, the usage of antibiotics beyond the 24-hour prophylaxis in patients who had 
post-decannulation SIRS phenomenon was similar between Group I and Group TS (antibiotics usage 
68%, length of use 8.7 ± 6.1 days in Group I vs. antibiotics usage 53%, length of use 6.5 ± 4.9 days in 
Group TS).  
A small number of the patients had procalcitonin levels measured after ECMO decannulation due 
to clinical suspicion of infection (22 patients in Group I and 8 patients in Group TS).  The mean 
procalcitonin was 3.3 ± 1.8 ng/dl in Group I and 1.8 ± 1.7 ng/dl in Group TS, p=0.2552.  The trend of 
higher procalcitonin values was observed more in Group I than in Group TS. 
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The post-decannulation 30-day survival rate was lower in Group I (77%, 17/22) than in Group TS 
(100%, 15/15) with p=0.047.  Of the five patients in Group I who died within 30 days, three of those 
deaths were related to post-decannulation infection (two due to infection related to permanent left 
ventricular assist device implantation and subsequent open chest management unrelated to ECMO, one 
due to severe pneumonia which developed after ECMO decannulation), and the other two were related to 
cardiac arrest secondary to possible in-stent thrombosis after ECMO removal.  The survival of those who 
had post-decannulation infection carrying over from ECMO was 78% (7/9), which was similar to that of 
those who developed new infections after ECMO removal (77%, 10/13).  
Based on the SIRS phenomenon criteria, there were 25 patients who did not have the SIRS 
phenomenon.  Among these patients without SIRS phenomenon, 10 patients (40%) had evidence of 
infection and 15 patients (60%) had no evidence of infection.  The survival rates were 60% and 87%, 
respectively (p=0.126).  
Discussion  
This study showed a frequent incidence of the SIRS phenomenon including fever, elevation of 
WBC, and hypotension requiring vasopressors after decannulation of ECMO, even though none of these 
patients have the SIRS phenomenon before decannulation of ECMO.  Almost all patients developed one 
of the three criteria of the post-decannulation SIRS phenomenon, and two-thirds of the patients fell under 
our definition of the SIRS phenomenon.  Although risk factor analyses showed pre-ECMO high lactate 
and low alanine aminotransferase were associated with development of the SIRS phenomenon after 
ECMO decannulation, we believe this pre-ECMO metabolic disarrangement most likely does not 
contribute an essential role to the development of the SIRS phenomenon since these levels were 
normalized before decannulation (Table 1).  Thus, the risk factors for development of the post-
decannulation SIRS phenomenon remain undetermined.  
Among those who had the SIRS phenomenon, the patterns of fever, leukocytosis and vasopressor 
requirements were almost identical between those who had infection and those who did not, although the 
outcomes were significantly inferior in the patients who had infections compared to those who had true 
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SIRS.  Once patients developed the SIRS phenomenon after ECMO decannulation, it could continue for 
almost a week regardless of the presence of infection.  However, a survival difference was clear based on 
the presence of infection.  The only difference in the SIRS phenomenon criteria between Group I and TS 
was the highest WBC count.  Patients with infection developed higher WBC counts; although patients 
with true SIRS also had elevated WBC count.  Although leukocytosis is not specific to infection, a WBC 
count greater than 30,000 is more likely infectious in etiology.  Extensive work up is necessary in these 
patients, and empiric antibiotics are recommended. 
The high incidence of the post-ECMO decannulation SIRS phenomenon is unique and has not 
previously been noted in the literature.  Although Aubron et al. demonstrated that bleeding is a frequent 
complication of ECMO, 6 our study showed that neither bleeding events or transfusion requirement did 
not significantly impact the development of SIRS or infections after ECMO decannulation.  
Peri-operative antibiotics were used for 24 hours after ECMO decannulation, unless the patient 
had ongoing treatment for infection during or prior to the ECMO period.  Identifying the infection shortly 
after ECMO decannulation may be challenging.  Our study showed that among those who had the SIRS 
phenomenon, more than half (~ 60%) of the patients had a significant infection, which affected the 30-day 
survival.  Patients with the SIRS phenomenon with a suspected infection should be treated aggressively 
with broad-spectrum antibiotics until culture results are available.  Due to lack of clear clinical 
differentiation between infection and the SIRS phenomenon, empiric antibiotics were often employed in 
these patients.  This may potentially increase costs and antimicrobial resistance; however, we did not 
analyze these variables. 
Although infection is a risk factor for post-decannulation death, it may be difficult to identify 
infections since finalized culture results may take up to 5 days.  Since 2012, we have used the 
procalcitonin level as a part of the work up for infection in conjunction with routine cultures. 7   
Procalcitonin is a biomarker of infection and has been reported to be more specific than WBC count or C-
reactive protein.  Based on our previous study, 7 the procalcitonin level used to identify infection was 2 
ng/dl.7  Among patients who had a procalcitonin level measured after ECMO decannulation, we found a 
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trend of higher procalcitonin values in Group I than in Group TS, although the sample size was too small 
to conclude statistical significance.  Since the procalcitonin value can be obtained as a point of care assay 
within hours of collection of the sample, procalcitonin may have a role in the early prediction of infection 
in patients with SIRS phenomenon after decannulation of ECMO. 
This study has limitations due to a small sample size, single institution practice, and retrospective 
nature.  Identification of infection was also a limitation.  We defined infection as the presence of positive 
culture results; however, the culture results may be dependent on the use of antibiotics.  The use of 
antibiotics in patients with the SIRS phenomenon was determined by the clinical judgment of a multi-
disciplinary intensive care team with infectious disease consultation.  Since post-decannulation infection 
increased the mortality in this study, routine prolonged courses of broad-spectrum antibiotics could be 
considered to minimize the risk of the post-decannulation infection, although this incidence of surgical 
site infection in this study was minimal.  Future multi-centered studies with larger patient populations 
would be necessary to further investigate this post-ECMO SIRS phenomenon, along with standardizing 
decannulation techniques, assessment of infection, and antimicrobial management strategies. 
Conclusions 
Both post-ECMO SIRS phenomenon (~60%) and post-decannulation infection (~60% including 
infection carried over during ECMO, and ~35% newly developed infection after ECMO decannulation) 
were common in our single institution experience.  The differentiation of infection from true SIRS was 
difficult and remains challenging.  The outcomes of those who had infection after ECMO decannulation 
were poor, while 100% of true SIRS patients survived.  The SIRS phenomenon after ECMO 
decannulation should be treated as infection until proven otherwise in order to optimize hospital 
outcomes. 
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Table 1: Demographics of patients with and without SIRS phenomenon.  Data are expressed as number 
(%) or mean ± standard deviation. 
 
 SIRS  
Phenomenon 
n=37 
No SIRS 
Phenomenon 
n=25 
p-value 
Pre-ECMO Demographics    
Age (years) 48 ± 13 47 ± 15 0.787 
Male gender 29 (78%) 15 (60%) 0.118 
Cardiac ECMO 24 (65%) 12 (48%) 0.187 
Respiratory ECMO 13 (35%) 13 (52%) 0.187 
E-CPR 5 (14%) 5 (20%) 0.496 
Clinical diagnoses    
Cardiogenic Shock 25 (68%) 12 (48%) 0.123 
Post-cardiotomy failure 5 (14%) 1 (4.0%) 0.214 
Acute respiratory distress syndrome 10 (27%) 10 (40%) 0.284 
Pre-ECMO laboratory data    
White blood cell count (B/L) 13.1 ± 6.9 14.3 ± 7.7 0.533 
Creatinine (mg/dl) 1.5 ± 0.9 1.4 ± 0.8 0.648 
Bilirubin (mg/dl) 1.4 ± 1.6 1.3 ± 1.2  0.780 
Aspartate aminotransferase (IU/L) 160 ± 190  290 ± 419 0.151 
Alanine aminotransferase (IU/L) 93 ± 190  288 ± 440  0.041 
Lactate (mmol/L) 4.8 ± 4.6 2.9 ± 2.4 0.038 
Pre-ECMO Scores    
SAPS II 53.6 ± 15.1 56.5 ± 19.6  0.534 
APACHE II 28.2 ± 8.3 27.8 ± 7.3 0.842 
MELD 15.6 ± 7.6  13.7 ± 6.2 0.285 
Complication during ECMO    
Stroke 2 (5%) 0 (0%) 0.237 
Pneumonia 8 (22%) 4 (16%) 0.583 
Pre-Decannulation laboratory data    
White blood cell count (B/L) 16.2 ± 6.1 20 ± 8.9 0.096 
Platelet count (B/L) 124 ± 63 130 ± 61 0.735 
Creatinine (mg/dl) 1.2 ± 0.5 1.2 ± 0.9 1.000 
Bilirubin (mg/dl) 2.6 ± 3.2 1.7 ± 1.2  0.125 
Aspartate aminotransferase (IU/L) 68 ± 41 72 ± 89 0.834 
Alanine aminotransferase (IU/L) 71 ± 71 72 ± 62 0.953 
Lactate (mmol/L) 1.5 ± 0.5 1.8 ± 1.8 0.439 
Length of ECMO (days) 10 ± 5.1 8.8 ± 5.3 0.378 
Outcomes    
30-day survival 32 (86%) 19 (76%) 0.289 
SIRS Phenomenon    
Fever 35 (95%) 17 (68%) 0.005 
Leukocytosis 27 (73%) 4 (16%) 0.000 
Escalation of vasopressors 30 (81%) 11 (44%) 0.003 
Infection 22 (59%) 10 (40%) 0.133 
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Table 2: Demographics of patients for Group I (Infection group) and Group TS (True SIRS group).  Data 
are expressed as number (%) or mean ± standard deviation. 
 
 Group I 
N=22 
Group TS 
N=15 
p-value 
Pre-ECMO Demographics    
Age (years) 51 ± 14 45 ± 13 0.222 
Male gender 18 (82%) 11 (73%) 0.538 
Cardiac ECMO 15 (68%) 9 (60%) 0.609 
Respiratory ECMO 7 (32%) 6 (40%) 0.609 
E-CPR 4 (18%) 1 (6.7%) 0.314 
Clinical risk factors    
Coronary artery disease 12 (55%) 4 (27%) 0.093 
Post-cardiotomy failure 2 (9.1%) 3 (20%) 0.341 
Acute respiratory distress syndrome 6 (27%) 4 (27%) 0.968 
Pre-ECMO laboratory data    
White blood cell count (B/L) 14.5 ± 8 11.1 ± 4.3 0.104 
HCO3 (mmol/L) 23 ± 6 19 ± 5 0.038 
Creatinine (mg/dl) 1.6 ± 0.8 1.4 ± 1.0 0.522 
Bilirubin (mg/dl) 1.5 ± 1.6  1.4 ± 1.7 0.866 
Aspartate aminotransferase (IU/L) 134 ± 196 189 ± 376 0.615 
Alanine aminotransferase (IU/L) 67 ± 71 123 ± 269 0.440 
Lactate (mmol/L) 4.6 ± 5.2  5.0 ± 3.7 0.795 
Pre-ECMO Scores    
SAPS II 55 ± 15  52 ± 15 0.558 
APACHE II 28 ± 7 29 ± 10  0.752 
MELD 17 ± 7 14 ± 8 0.271 
Complication during ECMO    
Stroke 2 (9.1%) 0 (0%) 0.230 
Pneumonia 3 (14%) 2 (13%) 0.979 
Pre-Decannulation laboratory data    
White blood cell count (B/L) 16.6 ± 5.8 15.5 ± 6.7 0.608 
Platelet count (B/L) 128 ± 64 120 ± 63 0.695 
Creatinine (mg/dl) 1.3 ± 0.5 1.1 ± 0.6 0.295 
Bilirubin (mg/dl) 2.5 ± 3.5 2.6 ± 2.8 0.924 
Aspartate aminotransferase (IU/L) 60 ± 34 81 ± 48 0.153 
Alanine aminotransferase (IU/L) 57 ± 50 93 ± 91 0.172 
Lactate (mmol/L) 1.5 ± 0.6  1.5 ± 0.4 1.000 
Length of ECMO (days) 9.8 ± 4.7 10.7 ± 5.8 0.621 
Outcomes    
30-day survival 17 (77%) 15 (100%) 0.047 
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Table 3: Post-decannulation data.  Data are expressed as number (%) or mean ± standard deviation. 
 
 Group I 
n=22 
Group TS 
n=15 
p-value 
Incidence of fever 22 (100%) 13 (87%) 0.078 
First day of fever  (days from decannulation) 1.3 ± 2.3 0.7 ± 0.9 0.283 
Duration of fever (days) 7.6 ± 4.9 6.7 ± 6.0 0.650 
Incidence of leukocytosis (%) 16 (73%) 11 (73%) 0.968 
First day of leukocytosis  (days from decannulation) 1.3 ± 1.1  1.3 ± 1.1 1.000 
Peak of white blood cell count (B/L) 30.1 ± 13.3 21.3 ± 7.7 0.040 
Peak of white blood cell count above 30k (B/L) 7 (46%) 3 (14%) 0.026 
Duration of leukocytosis (days) 7.3 ± 4.5 6.0 ± 4.2 0.450 
Escalation of vasopressors (%) 9 (41%) 7 (47%) 0.729 
Duration of escalation of vasopressors (days) 5.9 ± 3.0 4.4 ± 2.6 0.303 
Usage of antibiotics beyond prophylaxis (%) 15 (68%) 8 (53%) 0.531 
Duration of antibiotics beyond prophylaxis (days) 8.7 ± 6.1 6.5 ± 4.9 0.366 
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Figure 1: Division of patient groups.  
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